Loading...

We've got a brand new version of Simply Wall St! Try it out

Medartis Holding

SWX:MED
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MED
SWX
CHF495M
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region. The last earnings update was 86 days ago. More info.


Add to Portfolio Compare Print
MED Share Price and Events
7 Day Returns
-2.8%
SWX:MED
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
-40%
SWX:MED
33.3%
CH Medical Equipment
12.3%
CH Market
MED Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medartis Holding (MED) -2.8% 7.9% -5.1% -40% - -
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • MED underperformed the Medical Equipment industry which returned 33.3% over the past year.
  • MED underperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Medartis Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medartis Holding. This is due to cash flow or dividend data being unavailable. The share price is CHF42.15.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medartis Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medartis Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:MED PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CHF CHF0.33
SWX:MED Share Price ** SWX (2019-11-14) in CHF CHF42.15
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medartis Holding.

SWX:MED PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:MED Share Price ÷ EPS (both in CHF)

= 42.15 ÷ 0.33

128.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medartis Holding is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Medartis Holding is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Medartis Holding's expected growth come at a high price?
Raw Data
SWX:MED PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 128.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
51.5%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:MED PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 128.65x ÷ 51.5%

2.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medartis Holding is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Medartis Holding's assets?
Raw Data
SWX:MED PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CHF CHF19.53
SWX:MED Share Price * SWX (2019-11-14) in CHF CHF42.15
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:MED PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:MED Share Price ÷ Book Value per Share (both in CHF)

= 42.15 ÷ 19.53

2.16x

* Primary Listing of Medartis Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medartis Holding is good value based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Medartis Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Medartis Holding has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medartis Holding expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medartis Holding expected to grow at an attractive rate?
  • Medartis Holding's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Medartis Holding's earnings growth is expected to exceed the Switzerland market average.
  • Medartis Holding's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:MED Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:MED Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 51.5%
SWX:MED Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 17.8%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:MED Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:MED Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 192 11 1
2020-12-31 146 6 1
2019-12-31 129 3 1
2019-11-14
SWX:MED Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-06-30 125 5 4
2019-03-31 123 6 4
2018-12-31 121 6 4
2018-09-30 119 9 2
2018-06-30 116 11 0
2018-03-31 111 11 0
2017-12-31 105 11 1
2016-12-31 93 12 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medartis Holding's earnings are expected to grow significantly at over 20% yearly.
  • Medartis Holding's revenue is expected to grow by 17.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:MED Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Medartis Holding Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:MED Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.94 0.94 0.94 1.00
2020-12-31 0.48 0.48 0.48 1.00
2019-12-31 0.27 0.27 0.27 1.00
2019-11-14
SWX:MED Past Financials Data
Date (Data in CHF Millions) EPS *
2019-06-30 0.33
2019-03-31 0.36
2018-12-31 0.40
2018-09-30 0.16
2018-06-30 -0.05
2018-03-31 0.02
2017-12-31 0.12
2016-12-31 0.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Medartis Holding is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Medartis Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medartis Holding has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medartis Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medartis Holding's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medartis Holding's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Medartis Holding has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Medartis Holding has become profitable in the last year making it difficult to compare the CH Medical Equipment industry average.
Earnings and Revenue History
Medartis Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medartis Holding Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:MED Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 124.77 3.69 84.44 13.88
2019-03-31 123.05 3.94 83.09 13.56
2018-12-31 121.32 4.20 81.73 13.23
2018-09-30 118.90 1.87 79.73 12.99
2018-06-30 116.47 -0.45 77.74 12.75
2018-03-31 110.75 0.21 72.17 12.06
2017-12-31 105.04 0.87 66.59 11.36
2016-12-31 92.50 3.31 53.81 9.46
2015-12-31 82.30 7.27 47.16 8.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Medartis Holding has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Medartis Holding used its assets less efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Medartis Holding's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Medartis Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medartis Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medartis Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medartis Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medartis Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medartis Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medartis Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 71.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medartis Holding Company Filings, last reported 4 months ago.

SWX:MED Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 216.61 4.21 105.44
2019-03-31 216.61 4.21 105.44
2018-12-31 218.23 0.00 116.26
2018-09-30 218.23 0.00 116.26
2018-06-30 214.33 4.45 122.82
2018-03-31 214.33 4.45 122.82
2017-12-31 17.04 69.03 1.97
2016-12-31 19.08 61.55 1.76
2015-12-31 -44.98 120.75 1.35
  • Medartis Holding's level of debt (1.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Medartis Holding's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (186.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.8x coverage).
X
Financial health checks
We assess Medartis Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medartis Holding has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medartis Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medartis Holding dividends. Estimated to be 0% next year.
If you bought CHF2,000 of Medartis Holding shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medartis Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medartis Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:MED Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:MED Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2019-11-14

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medartis Holding has not reported any payouts.
  • Unable to verify if Medartis Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medartis Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medartis Holding has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Medartis Holding's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Medartis Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medartis Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medartis Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medartis Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christoph Brönnimann
AGE 53
TENURE AS CEO 0.2 years
CEO Bio

Mr. Christoph Brönnimann has been Chief Executive Officer and Member of Executive Management Board of Medartis Holding AG since September 1, 2019 and has responsibility for the sales organisation since November 1, 2019. Mr. Brönnimann has a successful international track record in medical technology management positions. In 2005, he joined Synthes, where he was responsible for the global integration of Stratec and Mathys and held various leadership roles in larger organizational units. Among other things, he was responsible for global quality management and new product approvals and oversaw international logistics. He later became General Manager of Synthes Switzerland. At Johnson & Johnson, following its acquisition of Synthes, he was first responsible for DePuySynthes Germany and then headed the J&J ONE Medical Device unit for Germany, Switzerland and Austria as a Member of the Medical Devices Europe Executive Board. Prior to his time at J&J and Synthes, his roles included working at PwC in M&A consulting and corporate finance. He began his career at Roche, where he worked in marketing and product management in the US from 1996 to 2000. He has a PhD in chemistry from ETH Zurich and completed a General Management Program at Harvard Business School.

CEO Compensation
  • Insufficient data for Christoph to compare compensation growth.
  • Insufficient data for Christoph to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Medartis Holding management team in years:

5.4
Average Tenure
49
Average Age
  • The average tenure for the Medartis Holding management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Christoph Brönnimann

TITLE
CEO & Member of Executive Management Board
AGE
53
TENURE
0.2 yrs

Dominique Leutwyler

TITLE
CFO, Deputy CEO & Member of Executive Management Board
AGE
49
TENURE
18.8 yrs

Axel Maltzen

TITLE
Chief Production Officer & Member of Executive Management Board
AGE
50
TENURE
5.4 yrs

Thomas Tribelhorn

TITLE
CTO & Member of Executive Management Board
AGE
49
TENURE
7.1 yrs

Anthony Durieux-Menage

TITLE
Chief Human Resources Officer & Member of the Executive Management Board
AGE
45
TENURE
0.8 yrs

Patrick Christ

TITLE
Head of Corporate Services
AGE
49
Board of Directors Tenure

Average tenure and age of the Medartis Holding board of directors in years:

9.8
Average Tenure
57
Average Age
  • The tenure for the Medartis Holding board of directors is about average.
Board of Directors

H. C. Straumann

TITLE
Chairman
AGE
56
TENURE
22.8 yrs

Dominik Ellenrieder

TITLE
Vice-Chairman
AGE
61
TENURE
17.8 yrs

Roland Hess

TITLE
Director
AGE
68
TENURE
2.8 yrs

Willi Miesch

TITLE
Director
AGE
55
TENURE
9.8 yrs

Jürg Greuter

TITLE
Director
AGE
63
TENURE
22.8 yrs

Daniel Herren

TITLE
Director
AGE
57
TENURE
2.8 yrs

Damien Tappy

TITLE
Director
AGE
50
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Medartis Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medartis Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well

SWX:MED Historical Debt, September 2nd 2019 How Strong Is Medartis Holding's Balance Sheet? … While Medartis Holding has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. … Summing up While we empathize with investors who find debt concerning, you should keep in mind that Medartis Holding has net cash of CHF116.3m, as well as more liquid assets than liabilities.

Simply Wall St -

Could The Medartis Holding AG (VTX:MED) Ownership Structure Tell Us Something Useful?

Check out our latest analysis for Medartis Holding SWX:MED Ownership Summary, August 15th 2019 What Does The Institutional Ownership Tell Us About Medartis Holding? … We can see that Medartis Holding does have institutional investors; and they hold 14% of the stock. … Insider Ownership Of Medartis Holding While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Those Who Purchased Medartis Holding (VTX:MED) Shares A Year Ago Have A 19% Loss To Show For It

Unfortunately the Medartis Holding AG (VTX:MED) share price slid 19% over twelve months. … Medartis Holding may have better days ahead, of course; we've only looked at a one year period. … During the last year Medartis Holding grew its earnings per share, moving from a loss to a profit.

Simply Wall St -

Should Medartis Holding AG (VTX:MED) Focus On Improving This Fundamental Metric?

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Medartis Holding: 1.9% = CHF4.2m ÷ CHF218m (Based on the trailing twelve months to December 2018.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … How Does Debt Impact Return On Equity? … Medartis Holding's Debt And Its 1.9% ROE Although Medartis Holding does use a little debt, its debt to equity ratio of just 0.015 is very low.

Simply Wall St -

Examining Medartis Holding AG’s (VTX:MED) Weak Return On Capital Employed

Analysts use this formula to calculate return on capital employed: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Medartis Holding: 0.026 = CHF6.1m ÷ (CHF256m - CHF20m) (Based on the trailing twelve months to December 2018.) So, Medartis Holding has an ROCE of 2.6%. … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE. … Medartis Holding has a low level of current liabilities, which have a negligible impact on its already low ROCE.

Simply Wall St -

What Kind Of Shareholder Appears On The Medartis Holding AG's (VTX:MED) Shareholder Register?

A look at the shareholders of Medartis Holding AG (VTX:MED) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of CHF656m, Medartis Holding is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Did Changing Sentiment Drive Medartis Holding's (VTX:MED) Share Price Down By 16%?

Unfortunately the Medartis Holding AG (VTX:MED) share price slid 16% over twelve months. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … During the last year Medartis Holding saw its earnings per share drop below zero.

Simply Wall St -

Is Medartis Holding AG (VTX:MED) Worth CHF55.40 Based On Intrinsic Value?

Today, I will calculate the stock's intrinsic value. … by projecting its future cash flows and then discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Do Insiders Own Shares In Medartis Holding AG (VTX:MED)?

The big shareholder groups in Medartis Holding AG (VTX:MED) have power over the company. … With a market capitalization of CHF816m, Medartis Holding is a decent size, so it is probably on the radar of institutional investors. … View our latest analysis for Medartis Holding

Simply Wall St -

Is Medartis Holding AG's (SWX:MED) Stock Available For A Good Price After Accounting For Growth?

Medartis Holding AG (SWX:MED) is considered a high growth stock. … However its last closing price of CHF61.4 left investors wondering whether this growth has already been factored into the share price. … Medartis Holding's extremely high growth potential in the near future is attracting investors

Simply Wall St -

Company Info

Description

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region. The company offers plates and screws solutions to treat various fractures, osteotomies, and degenerative diseases of hand, wrist, elbow, shoulder, and foot and ankle under the APTUS name; and implants for fracture fixations and osteotomies in the mandibular, and midface and cranial regions under the MODUS name. Medartis Holding AG’s products also used in tumor reconstruction and orthognathic deformities of the skull. The company sells its products through a network of direct sales representatives primarily to surgeons, hospitals, and medical centers, as well as to group purchasing organizations worldwide. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.

Details
Name: Medartis Holding AG
MED
Exchange: SWX
Founded: 1997
CHF494,883,445
11,741,007
Website: http://www.medartis.com
Address: Medartis Holding AG
Hochbergerstrasse 60E,
Basel,
Basel-Stadt, 4057,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX MED Register Shares SIX Swiss Exchange CH CHF 22. Mar 2018
Number of employees
Current staff
Staff numbers
588
Medartis Holding employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 22:09
End of day share price update: 2019/11/14 00:00
Last estimates confirmation: 2019/10/07
Last earnings filing: 2019/08/20
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.